WO2000015773A9 - Inhibition de transcription d'oncogenes par des polyamides synthetiques - Google Patents
Inhibition de transcription d'oncogenes par des polyamides synthetiquesInfo
- Publication number
- WO2000015773A9 WO2000015773A9 PCT/US1999/020489 US9920489W WO0015773A9 WO 2000015773 A9 WO2000015773 A9 WO 2000015773A9 US 9920489 W US9920489 W US 9920489W WO 0015773 A9 WO0015773 A9 WO 0015773A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polyamide
- correspond
- dsdna
- nucleotide
- sequence
- Prior art date
Links
- 239000004952 Polyamide Substances 0.000 title claims abstract description 231
- 229920002647 polyamide Polymers 0.000 title claims abstract description 231
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 64
- 230000035897 transcription Effects 0.000 title claims abstract description 60
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims abstract description 153
- 239000011528 polyamide (building material) Substances 0.000 claims abstract description 128
- 229920001850 Nucleic acid sequence Polymers 0.000 claims abstract description 37
- 230000000295 complement Effects 0.000 claims abstract description 22
- 230000027455 binding Effects 0.000 claims description 102
- 239000002773 nucleotide Substances 0.000 claims description 41
- 125000003729 nucleotide group Chemical group 0.000 claims description 41
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 35
- -1 N,N- dimethylaminopropyl residue Chemical group 0.000 claims description 23
- 229940000635 beta-Alanine Drugs 0.000 claims description 17
- 235000018102 proteins Nutrition 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 11
- 229960003692 aminobutyric acid Drugs 0.000 claims description 11
- 229940013945 gamma-Aminobutyric Acid Drugs 0.000 claims description 11
- OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical compound NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 230000000051 modifying Effects 0.000 claims description 9
- 230000000875 corresponding Effects 0.000 claims description 7
- YMGBDORZBGLLER-UHFFFAOYSA-N 1-methylpyrrol-3-ol Chemical compound CN1C=CC(O)=C1 YMGBDORZBGLLER-UHFFFAOYSA-N 0.000 claims description 6
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid zwitterion Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 229960002449 Glycine Drugs 0.000 claims description 6
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-Methylimidazole Chemical group CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims description 5
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical group CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 claims description 5
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 25
- 102100009759 ELF3 Human genes 0.000 description 56
- 230000014509 gene expression Effects 0.000 description 42
- 230000015572 biosynthetic process Effects 0.000 description 40
- 239000003814 drug Substances 0.000 description 34
- 102000003995 transcription factors Human genes 0.000 description 34
- 108090000464 transcription factors Proteins 0.000 description 34
- 238000005755 formation reaction Methods 0.000 description 33
- 229940079593 drugs Drugs 0.000 description 32
- 101700025368 ERBB2 Proteins 0.000 description 31
- 102000027760 ERBB2 Human genes 0.000 description 26
- 101710039692 TFAP2A Proteins 0.000 description 26
- 102100004565 TFAP2A Human genes 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 20
- UPBAOYRENQEPJO-UHFFFAOYSA-N N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 19
- 108010042747 stallimycin Proteins 0.000 description 19
- 210000004027 cells Anatomy 0.000 description 18
- 239000000499 gel Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 230000002018 overexpression Effects 0.000 description 15
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 14
- 102100005468 TBP Human genes 0.000 description 14
- 238000004166 bioassay Methods 0.000 description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 14
- 230000004568 DNA-binding Effects 0.000 description 12
- 238000004448 titration Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 230000000699 topical Effects 0.000 description 11
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 10
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000001413 cellular Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 229920000272 Oligonucleotide Polymers 0.000 description 9
- 238000000211 autoradiogram Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 230000003612 virological Effects 0.000 description 9
- 238000007792 addition Methods 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 102100016662 ERBB2 Human genes 0.000 description 7
- 206010039491 Sarcoma Diseases 0.000 description 7
- 102000004965 antibodies Human genes 0.000 description 7
- 108090001123 antibodies Proteins 0.000 description 7
- 150000003857 carboxamides Chemical class 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000002194 synthesizing Effects 0.000 description 7
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 6
- LBZQAEQLSRWNLM-UHFFFAOYSA-N N-methyl-1H-pyrrole-2-carboxamide Chemical class CNC(=O)C1=CC=CN1 LBZQAEQLSRWNLM-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 102100015262 MYC Human genes 0.000 description 5
- OWWASHBXVFOTDF-UHFFFAOYSA-N N-methyl-1H-imidazole-2-carboxamide Chemical class CNC(=O)C1=NC=CN1 OWWASHBXVFOTDF-UHFFFAOYSA-N 0.000 description 5
- 229920003188 Nylon 3 Polymers 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 201000008808 fibrosarcoma Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229940022766 EGTA Drugs 0.000 description 4
- 206010015281 Erythroleukaemia Diseases 0.000 description 4
- 208000009503 Leukemia, Erythroblastic, Acute Diseases 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N Spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001603 reducing Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- OGNSCSPNOLGXSM-GSVOUGTGSA-N (2R)-2-amino-4-azaniumylbutanoate Chemical compound NCC[C@@H](N)C(O)=O OGNSCSPNOLGXSM-GSVOUGTGSA-N 0.000 description 3
- 101700039191 EGFR Proteins 0.000 description 3
- 101700079540 FAS Proteins 0.000 description 3
- 206010027476 Metastasis Diseases 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 3
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 3
- 101710037934 QRSL1 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001594 aberrant Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101700068417 fol1 Proteins 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 230000001177 retroviral Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1H-pyrrole-2-carboxamide Chemical class NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000031025 DNA-Binding Proteins Human genes 0.000 description 2
- 108091000102 DNA-Binding Proteins Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102100009768 ETS1 Human genes 0.000 description 2
- 101700033664 ETS1 Proteins 0.000 description 2
- 108010066668 ErbB-2 Receptor Proteins 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710004181 INTS2 Proteins 0.000 description 2
- 101710033922 KRAS Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920001007 Nylon 4 Polymers 0.000 description 2
- 229920002292 Nylon 6 Polymers 0.000 description 2
- 102100019756 OTUD4 Human genes 0.000 description 2
- 101700060279 OTUD4 Proteins 0.000 description 2
- 229940113116 Polyethylene Glycol 1000 Drugs 0.000 description 2
- 101710022291 SCGB3A1 Proteins 0.000 description 2
- 101710009384 SRC Proteins 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- PGAVKCOVUIYSFO-XVFCMESISA-N Uridine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000003281 allosteric Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 102000024070 binding proteins Human genes 0.000 description 2
- 108091007650 binding proteins Proteins 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000002103 transcriptional Effects 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 102000035402 transmembrane proteins Human genes 0.000 description 2
- 108091005683 transmembrane proteins Proteins 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229950010342 uridine triphosphate Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- FHIDNBAQOFJWCA-MNCSTQPFSA-N 1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoropyrimidine-2,4-dione Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-MNCSTQPFSA-N 0.000 description 1
- ZPOROQKDAPEMOL-UHFFFAOYSA-N 1H-pyrrol-3-ol Chemical compound OC=1C=CNC=1 ZPOROQKDAPEMOL-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108060006693 ABL Proteins 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000209134 Arundinaria Species 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 208000000409 Breast Neoplasms Diseases 0.000 description 1
- MREIFUWKYMNYTK-UHFFFAOYSA-N C=1C=CNC=1.C=1C=CNC=1 Chemical compound C=1C=CNC=1.C=1C=CNC=1 MREIFUWKYMNYTK-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 210000004671 Cell-Free System Anatomy 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 210000003483 Chromatin Anatomy 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 102000008422 EC 2.7.1.78 Human genes 0.000 description 1
- 108010021757 EC 2.7.1.78 Proteins 0.000 description 1
- 102000001301 EGF receptors Human genes 0.000 description 1
- 108060006698 EGF receptors Proteins 0.000 description 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
- 210000004696 Endometrium Anatomy 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 description 1
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229940014144 Folate Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101710033925 HRAS Proteins 0.000 description 1
- 102100009283 HRAS Human genes 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100012486 JUN Human genes 0.000 description 1
- 108060001040 JUN Proteins 0.000 description 1
- 102100009279 KRAS Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 101700057214 MSRA Proteins 0.000 description 1
- 102100013489 MSRA Human genes 0.000 description 1
- 101700053140 MSRA4 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- DMOMFSUPEGKPKO-UHFFFAOYSA-N N-[5-[[5-[3-(dimethylamino)propylcarbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-1-methylimidazole-2-carboxamide Chemical compound CN1C(C(=O)NCCCN(C)C)=CC(NC(=O)C=2N(C=C(NC(=O)C=3N(C=CN=3)C)C=2)C)=C1 DMOMFSUPEGKPKO-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 229920000571 Nylon 11 Polymers 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 210000003101 Oviducts Anatomy 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002224 Peptide nucleic acid Polymers 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 102100016115 RAF1 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- YZHUMGUJCQRKBT-UHFFFAOYSA-M Sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 102000005610 Thyroid Hormone Receptors alpha Human genes 0.000 description 1
- 108010045070 Thyroid Hormone Receptors alpha Proteins 0.000 description 1
- 102000004893 Transcription factor AP-2 Human genes 0.000 description 1
- 108090001039 Transcription factor AP-2 Proteins 0.000 description 1
- 229920001949 Transfer RNA Polymers 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- 101710019504 XAB2 Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 108091008123 c-sis Proteins 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-N calcium;sulfuric acid Chemical compound [Ca+2].OS(O)(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940020899 hematological Enzymes Drugs 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000006439 lymphocytic leukemia Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 102000034377 signal transducing proteins Human genes 0.000 description 1
- 108091006008 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Definitions
- This invention relates to specific polyamides that bind to predetermined nucleotide sequences in the minor groove of double-stranded DNA (dsDNA) located within the promoter region of a gene to prevent expression of endogenous oncogenes.
- dsDNA double-stranded DNA
- HER2/neu The tyrosine kinase membrane growth factor receptor HER2/neu, also known as pl85HER2 ? [ s encoded by a cellular oncogene of the same name that is overexpressed and amplified in 20 to 30% of human breast cancers, among others, including human gynecologic adenocarcinomas, such as those of the ovary, endometrium, fallopian tube, and cervix. See Baert, J.-L. et al, Int. J. Cancer 70, 590-597 (1997); Benz, C, et al, Oncogene 15, 1513-1525 (1997); Chang, C.-H., et al, Oncogene 14, 1617-1622 (1997); Scott, G.
- Her-2/neu was found to be homologous to the EGF receptor, a 185 kDa transmembrane protein with protein tyrosine kinase activity. Overexpression of HER2/neu is also associated with the likelihood that tumors will metastasize, with a resulting poor prognosis for the patient. Mutation, amplification, and overexpression of the Her-2/neu oncogene has been reported to be associated with breast tumor progression, early metastasis and poor prognosis. Her-2/neu gene amplification directly correlates with lymph node metastasis. Additionally, in an animal model, activating mutations lead to rapid tumor progression. As a result, it is believed that the Her-2/neu protein likely plays a role in cell motility and hence in metastasis. Thus, inhibition of Her-2/neu gene expression by direct interference at the DNA level may be a potent therapeutic approach for metastatic disease.
- transcription factors - such as ESX, AP-2, and TBP - play an important role in the regulation of the expression of this receptor. See Baert, et al, supra; Benz, et al, supra; Chang, et al, supra; Bosher, J. M., et al, Proc. Natl Acad. Sci. USA 92, 744- 747 (1995).
- These transcription factors activate the expression of pl85HER2 upon binding to sites within the HER2/neu promoter.
- the nucleotide sequence of the HER2/neu promoter and a schematic representation are shown in Figure 1. While the ESX binding site and the TBP binding site (TATA box) are close to each other, the OB2- 1 (a member of the AP-2 transcription factor family) site is located about 180 base pairs further upstream.
- ESX belongs to the Ets family of transcription factors. Ets proteins bind in a winged helix-turn-helix motif to the major groove of DNA contacting the minor groove on the flanking sides of the binding site.
- AP-2 binds as a dimer to the major groove of DNA; its DNA binding region is organized in a manner similar to that of a leucine zipper protein. Williams, T. & Tjian, R. Science 251, 1067-1071 (1991).
- the structural element that is responsible for the DNA binding as well as for the protein/protein interaction (dimerization) is predicted to consist of a helix-span-helix motif. It is not clear if the span subunit that consists of about 80 amino acids contacts the minor groove of DNA.
- TBP is a ubiquitous transcription factor that is involved in the activation of most protein-encoding genes.
- TBP is a DNA-binding protein that interacts with the minor groove of double-stranded DNA ("dsDNA"). It should be noted that, apart from ESX, AP-2, and TBP, there are other potential transcription factor binding sites within the HER2/neu and other oncogene promoters.
- the agent must not possess any general cell toxicity; second, the agent must be cell-permeable and, in the case of the DNA-binding agents, the compounds must transit to the nucleus and bind their target sequence with high affinity and specificity in the context of cellular chromatin; and, third, binding of the agent to its DNA target sequence must interfere with gene transcription.
- the potential approaches listed above has its own peculiar limitations. For example, while triple helix-forming oligonucleotides have the potential for sequence selectivity and can effectively inhibit transcription in vitro, these molecules suffer from poor cell permeability and permeabilized cells need to be used for effective gene inhibition.
- calicheamicin oligosaccharides are sufficiently hydrophobic to pass through cell membranes, but these molecules possess severely limited sequence specificity (4 bp) and bind DNA with very low affinities (100 ⁇ M or higher required for inhibition of protein-DNA interactions).
- sequence specificity 4 bp
- affinities 100 ⁇ M or higher required for inhibition of protein-DNA interactions
- Another approach utilizes cell-permeable small molecules that target particular
- DNA sequences are useful for the regulation of gene expression.
- the design of small synthetic DNA-binding ligands that recognize specific sequences in the DNA double helix has been a long standing goal of chemistry. Oligodeoxynucleotides that recognize the major groove of double-helical DNA via triple- helix formation bind to a broad range of sequences with high affinity and specificity. Although oligonucleotides and their analogs have been shown to interfere with gene expression, the triple helix approach is limited to purine tracks and suffers from poor cellular uptake.
- polyamides Since a six base-pair sequence would be highly redundant in the human genome (occurring at random once every 4 kilobases, or 500,000 times in the human genome), polyamides have been synthesized to recognize much longer sequences. For example, a twelve-ring double hairpin polyamide has been designed to target a 12 bp site and binding is again observed with nanomolar affinity. Such a sequence would be predicted to occur at random only once every 16 million base pairs, or only 125 times in the human genome. Such molecules thus have the potential to act as specific inhibitors of gene transcription in vivo and as human therapeutic agents if the conditions outlined above can be met.
- the present invention relates to and includes methods and compositions for the modulation, or regulation, of gene expression or overexpression by reducing the transcription of genes, particularly oncogenes.
- the transcription of specific individual target oncogenes is reduced or inhibited.
- Such reductions result from the application of polyamides that bind or interact with the minor groove of double-stranded DNA (dsDNA) within the promoter region of a target gene.
- dsDNA double-stranded DNA
- the binding or interaction is with a predetermined target nucleic acid sequence within the promoter region to inhibit or down-regulate transcription.
- promoter refers to nucleic acid sequences needed for gene expression, and includes the region of DNA involved in binding RNA polymerase to initiate transcription of the gene associated with the promoter. It also includes sequences that bind other proteins that facilitate RNA polymerase' s association with DNA in order to initiate transcription. Promoters can also include enhancer regions.
- the present invention reduces gene expression and overexpression by use of sequence-specific DNA-binding small molecules that are cell-permeable and capable of inhibiting oncogene transcription. Appropriate application of such molecules may inhibit aberrant expression or activation of endogenous oncogenes to provide a fundamentally new therapeutic strategy for the treatment of various diseases, including cancer.
- the small molecules of the invention are polyamides that bind to or interact with nucleic acid sequences within the promoter region of target genes. Preferably, these sequences are recognized, or proximal to those that are recognized, by one or more transcription factors.
- the polyamide compounds of the invention bind to dsDNA according to pairing rules for polyamide subunit recognition of nucleotide bases. More specifically, derivatives of pyrrole, imidazole, 3-hydroxypyrrole, and strategically positioned aliphatic amino acid residues form structures that recognize specific, targeted nucleotide base pairs in the minor groove of dsDNA. Selected aromatic and aliphatic amino acids may also be incorporated into polyamides, which residues remain unpaired with other amino acid residues. The polyamide molecules have a crescent-shaped form that allows them to complex with the minor groove of double-stranded DNA.
- polyamides can be covalently linked by a turn- unit such as ⁇ -aminobutyric acid. Mrksich, et al, J. Am. Chem. Soc. 116, 7983 (1994).
- Such polyamides are called "hairpin polyamides", as they adopt a hairpin-like conformation in the DNA complex.
- the sequence of the imidazole and the pyrrole carboxamides in the polyamide determines the DNA sequence specificity of the ligand, according to the scheme of carboxamide pairs that recognize nucleotide pairs described above.
- polyamides By using Hp together with Py and Im in four pairs of aromatic amino acid residues (Im/Py, Py/Im, Hp/Py, and Py/Hp) polyamides can be designed and synthesized that selectively distinguish all four Watson-Crick base pairs in the minor groove of double stranded DNA.
- the invention encompasses improved polyamides for binding to the minor groove of DNA as well as methods for the design and synthesis of specific polyamides that correspond to and bind selectively to a nucleotide sequence of a desired target DNA.
- the preparation and use of polyamides for binding in the minor groove of DNA are extensively described in the art.
- improved polyamides are employed that utilize 3-hydroxy-N-methylpyrrole to provide Hp/Py carboxamides to bind to a T*A base pair in the minor groove of DNA or Py/Hp carboxamide binding pair in the polyamide to bind to an A*T base pair in the minor groove of DNA.
- this invention provides polyamides having three or more carboxamide binding pairs that will distinguish A»T, T «A, C*G, and G*C base pairs in the minor groove of dsDNA.
- the invention encompasses polyamides having ⁇ - aminobutyric acid to form a hairpin-loop with a member of each carboxamide pairing on each side of it.
- the ⁇ -aminobutyric acid is a chiral (R)-2,4-diaminobutyric acid.
- the invention also encompasses polyamides containing a ⁇ -alanine substituted for a Py that would ordinarily be used in a carboxamide binding pair to match a particular nucleotide pair.
- the ⁇ -alanine is referred to in formulas as ⁇ .
- the ⁇ becomes a member of a carboxamide binding pair, and serves to optimize hydrogen bonding of neighboring amino acid moieties to nucleotide base pairs.
- the invention further includes the substitution as a ⁇ * ⁇ binding pair for non-Hp containing binding pair.
- binding pairs in addition to the Hp/Py and Py/Hp are Py/Py, Im/Py, Py/Im, Im/ ⁇ , ⁇ /Im, Py/ ⁇ , ⁇ /Py, and ⁇ / ⁇ .
- the invention provides polyamides suitable for inhibiting the transcription of an endogenous oncogene, wherein the polyamides comprise at least three complementary pairs of aromatic carboxamide residues, the complementary pairs of aromatic carboxamide residues being selected to correspond to the nucleotide sequence of an identified dsDNA target, including at least two aliphatic amino acid residues chosen from the group consisting of glycine, ⁇ -alanine, ⁇ -aminobutyric acid, R 2,4- diaminobutyric acid, and 5-aminovaleric acid, and at least one terminal alkylamino residue.
- the complementary pairs of aromatic carboxamide residues selected to correspond to the nucleotide sequence of an identified dsDNA target are chosen from the group consisting of Im/Py to correspond to the nucleotide pair G/C, Py/Im to correspond to the nucleotide pair C/G, Py/Py to correspond to the nucleotide pair A/T, Py/Py to correspond to the nucleotide pair T/A, Hp/Py to correspond to the nucleotide pair T/A, and Py/Hp to correspond to the nucleotide pair A/T, where Im is N-methyl imidazole, Py is N-methyl pyrrole and Hp is 3-hydroxy N-methyl pyrrole.
- the polyamides of the invention can also be used to prevent, inhibit, or reduce transcription from a viral oncogene.
- the polyamides bind to the minor groove of double-stranded DNA in a promoter region that controls the transcription and expression of an oncogene.
- the polyamides bind to the nucleotide sequence of an identified dsDNA target chosen from the group consisting of 5'-TGCTTGA-3', 5'-AGAATGA-3', 5'-TGAGGAA-3', 5'-TGCTTGA-3', 5'-TGAGGAA-3', 5'-AGGAAGT-3', 5'-ATGAAGT- 3', 5'-AGTATAA-3*, 5'-AGTATAA-3', 5'-AGGAAGT-3', 5*-AGTATAA-3', 5'- AGTATAA-3', 5*-AACGGCT-3', 5'-TGCAGGCA-3', 5'-AACGGCT-3', 5'- TGCAGGCA-3', and 5'-AGGCAA-3'.
- the transcription of the gene is inhibit
- Preferred polyamides comprise at least one aliphatic amino acid residue is ⁇ - alanine.
- the terminal alkylamino residue is a N,N- dimethylaminopropyl residue.
- Suitable polyamides can contain at least two ⁇ -alanine residues aligned to form complementary paired residues corresponding to a nucleotide pair chosen from the group A/T and T/A. Alternatively, corresponding pairs can be formed between aliphatic amino acids and aromatic carboxamides, such as Im/ ⁇ , ⁇ /Im, Py/ ⁇ and ⁇ /Py.
- a hairpin molecule is formed by a an aliphatic amino acid residue such as ⁇ -aminobutyric acid or more preferably R 2,4-diaminobutyric acid.
- Suitable polyamides have a binding affinity at the dsDNA target sequence of at least 10 9 M "1 and a selectivity of at least about two, selectivity being defined as the ratio of the binding affinity for the identified dsDNA target sequence to the binding affinity for a single base-pair mismatch dsDNA sequence. In preferred embodiments, selectivity against at least 90% of single base mismatch sequences is greater than about 10.
- the present invention provides polyamides suitable for inhibiting the transcription of an oncogene comprising at least three complementary pairs of aromatic carboxamide residues, the complementary pairs of aromatic carboxamide residues being selected to correspond to the nucleotide sequence of an identified dsDNA target, at least two aliphatic amino acid residues chosen from the group consisting of glycine, ⁇ -alanine, ⁇ - aminobutyric acid, R 2,4-diaminobutyric acid, and 5-aminovaleric acid, and at least one terminal alkylamino residue, the polyamide having a binding affinity at the target dsDNA sequence of at least 10 9 M "1 and a selectivity of at least about two, selectivity being defined as the ratio of the binding affinity for the identified target dsDNA sequence to the binding affinity for a single base-pair mismatch dsDNA sequence.
- the invention concerns compositions comprising a pharmaceutically acceptable excipient and a transcription-inhibiting amount of at least one polyamide according to the invention.
- the polyamides bind to the minor groove of double-stranded DNA in a promoter region that controls the transcription and expression of a gene, particularly an oncogene.
- the transcription of a selected oncogene is inhibited by modulating the binding of a protein transcription factor to dsDNA, preferably in the gene's promoter region.
- the transcription factors are ESX, ETS, AP-2, OB2- 1 ,and TBP.
- both classes of transcription factors can be inhibited by polyamides that contact or bind the minor groove of dsD A.
- D A complexation of proteins contacting the minor groove may be inhibited by direct steric hindrance, repulsion, or exclusion or, alternatively, by allosteric effects.
- the binding of major groove binding proteins may be suppressed by a polyamide-induced change of the DNA conformation.
- inhibition can also be achieved other ways, for example, by conjugating a DNA cleavage agent to a polyamide targeted to a desired site, or by chemically modifying DNA using a chemically reactive moiety attached to a polyamide.
- the expression or overexpression of oncogenes is reduced or inhibited by using a polyamide targeted to a specific nucleotide base sequence in dsDNA, particularly a target sequence in the promoter region of the particular oncogene.
- the oncogenes are viral or endogenous cellular oncogenes involved in cancer.
- One oncogene target of the invention is the HER-2/neu gene, which may be down-regulated or inhibited by the use of polyamides that bind to target sequences within the HER-2/neu promoter region.
- the sequences targeted by a polyamide are, or are proximal to, transcription factor binding sites within the oncogene promoter.
- Interactions or binding between the polyamide and the target sequence can inhibit the transcription of the targeted oncogene.
- the degree of inhibition of oncogene expression can be extensive, and includes the inhibition of overexpression, such that a level of expression correlated with a non-disease state is restored. Of course, even greater inhibition may be achieved, depending on the particular application.
- the invention further encompasses application of polyamides for the treatment of various tumors or cancers (including breast cancer) associated with oncogene expression.
- Suitable polyamides most preferably have a binding affinity at the dsDNA target sequence of at least 10 9 M "1 and a selectivity of at least about two. Selectivity is defined as the ratio of the binding affinity for the identified dsDNA target sequence to the binding affinity for a single base-pair mismatch dsDNA sequence. In preferred embodiments, selectivity against at least 90% of single base mismatch sequences is greater than about 10.
- compositions that comprise a pharmaceutically acceptable excipient and a transcription-inhibiting amount of at least one polyamide of the invention.
- Each polyamide contains at least three complementary pairs of aromatic carboxamide residues, which pairs are selected to correspond to an identified nucleotide sequence of a dsDNA target.
- the polyamides additionally comprise at least two aliphatic amino acid residues chosen from the group consisting of glycine, ⁇ -alanine, ⁇ -aminobutyric acid, R-2,4-diaminobutyric acid, and 5-aminovaleric acid, and at least one terminal alkylamino residue, the polyamide having a binding affinity at the target dsDNA sequence of at least 10 9 M "1 and a selectivity of at least about two, selectivity being defined as the ratio of the binding affinity for the identified target dsDNA sequence to the binding affinity for a single base- pair mismatch dsDNA sequence.
- the invention further provides methods suitable for treating a subject having a condition associated with abnormal expression of a cellular oncogene.
- the subject is preferably a human patient and, more particularly, one afflicted with breast cancer or other diseases or conditions associated with aberrant Her-2/neu oncogene expression.
- Figure 1 depicts the HER2/neu promoter, showing the nucleotide sequence in A, including binding sites of ESX, AP-2, OB2-1, and TBP ("TATA") transcription factors, and in B, a schematic diagram, not to scale, showing the ESX, TBP, and OB2-1 binding sites.
- Figure 2 in A shows the nucleotide sequence of the ESX binding site, indicating four overlapping polyamide target sites
- B the schematic structure of eight polyamides (1-8) that have been designed to bind to the nucleotide sequences of these target sites 1-4, in which N-methylimidazole carboxamides are represented by filled circles, N-methylpyrrole carboxamides by empty circles, and ⁇ -alanine amino acids by unfilled diamonds.
- 4-diaminobutyric acid is represented by a curved line bearing an amino group and the N,N-dimethylaminopropyl substituent (and the C-terminus) by a positively charged half-circle.
- Figure 3 illustrates a typical solid-phase synthesis scheme, using polyamide 1 as an example.
- Figure 4 shows the structural formulas of eight polyamides that have been designed to bind to the ESX binding site, as well as MALDI-MS data that characterize each compound.
- Figure 5 is a graphical representation of the results of a DNase I footprint titration of polyamide 1 on the 188 base-pair 5 '-end-labeled DNA fragment, showing in A an autoradiogram: lane 1, A reaction; lane 2 to 12, 20 pM, 40 pM, 80 pM, 100 pM, 200 pM, 400 pM, 1 nM, 2 nM, 4 nM 10 nM, 20 nM polyamide 1, all reactions containing 15 kcpm DNA fragment, 10 mM Tris HC1 (pH 7.0), 10 mM KC1, 10 mM MgCl2, and 5 mM CaCl2, the match- and the single base-pair mismatch site shown to the right side of the autoradiogram, and in B, the schematic structure of polyamide 1.
- Figure 6 summarizes the results of DNase I footprint titrations, showing in A, a portion of the nucleotide sequence of the HER2/neu promoter containing the ESX binding site with polyamide binding sites 1-4 indicated, and in B, the four polyamide target sites with corresponding schematic representations of polyamides 1-8.
- Figure 7 in A shows the nucleotide sequence of a AP-2 binding site, indicating three overlapping polyamide target sites, and in B, the schematic structure of five polyamides (9-13) that were designed to bind to the nucleotide sequences of these target sites 1-3.
- Figure 8 shows the structural formulas of five polyamide compounds designed to bind to the nucleotide sequence of the AP-2 binding site, as well as MALDI-MS data that characterize each compound.
- Figure 9 is a graphical representation of the results of a DNase I footprint titration of polyamide 9 on the 188 base-pair 5'-end-labeled DNA fragment, showing in A an autoradiogram: lane 1, A reaction; lane 2 to 12, 20 pM, 40 pM, 80 pM, 100 pM, 200 pM, 400 pM, 1 nM, 2 nM, 4 nM 10 nM, 20 nM polyamide 9, all reactions containing 15 kcpm DNA fragment, 10 mM Tris HC1 (pH 7.0), 10 mM KC1, 10 mM MgCl2, and 5 mM CaCl2, and in B, the schematic structure of polyamide 9.
- Figure 10 is a graphical representation of the results of a DNase I footprint titration of polyamide 10 on the 188 base-pair 5'-end-labeled DNA fragment, showing in A an autoradiogram: lane 1, A reaction; lane 2 to 12, 20 pM, 40 pM, 80 pM, 100 pM, 200 pM, 400 pM, 1 nM, 2 nM, 4 nM 10 nM, 20 nM polyamide 10, all reactions containing 15 kcpm DNA fragment, 10 mM Tris HC1 (pH 7.0), 10 mM KC1, 10 mM MgCl2, and 5 mM CaCl2, the match site shown to the right side of the autoradiogram, and in B, the schematic structure of polyamide 10.
- Figure 11 is a graphical representation of the results of a DNase I footprint titration of polyamide 13 on the 188 base-pair 5'-end-labeled DNA fragment, showing in A an autoradiogram: lane 1, A reaction; lane 2 to 12, 20 pM, 40 pM, 80 pM, 100 pM, 200 pM, 400 pM, 1 nM, 2 nM, 4 nM 10 nM, 20 nM polyamide 13, all reactions containing 15 kcpm DNA fragment, 10 mM Tris HCl (pH 7.0), 10 mM KCl, 10 mM MgCl2, and 5 mM CaCl2, the match site shown to the right side of the autoradiogram, and in B, the schematic structure of polyamide 13.
- Figure 12 summarizes the results of DNase I footprint titrations, showing in A a portion of the nucleotide sequence of the HER2/neu promoter containing the AP-2 binding site with polyamide binding sites 1-3 indicated, and in B, the three polyamide target sites with corresponding schematic representations of polyamides 9-13.
- Figure 13 is a graphical representation of the results of a gel shift experiment showing the binding of an oligonucleotide containing the ESX binding site of the HER2/neu promoter and the ESX protein in the presence of various concentrations of polyamide 2 (“PA-2E”) or distamycin.
- PA-2E polyamide 2
- Figure 14 is a graphical representation of a quantitative comparison of the inhibition of the ESX/DNA complex by polyamide 1 ("PA- IE”) and polyamide 2 (“PA- 2E") presented before exposure to ESX ("Before") or after the formation of the ESX/DNA complex ("After”).
- PA- IE polyamide 1
- PA- 2E polyamide 2
- Figure 15 is a graphical representation of a quantitative comparison of the ability of polyamides 1 (A) and 2 (B) to inhibit in vitro transcription driven by the HER2/neu promoter when the respective polyamides were presented before exposure to ESX ("Before") or after the formation of the ESX/DNA complex ("After”).
- Figure 16 is a graphical representation of a quantitative comparison of the inhibition of the ESX/DNA complex by polyamide 2 (“PA-2E”) or distamycin (“Dist”).
- Figure 17 is a graphical representation of a quantitative comparison of the inhibition of the formation of the ESX/DNA complex or the AP-2/DNA complex by polyamide 1 ("PA-IE”), polyamide 2 (“PA-2E”) or distamycin.
- Figure 18 is a graphical representation of a quantitative comparison of the inhibition of the formation of the ESX/DNA complex by polyamide 1 (“PA- IE”), polyamide 2 (“PA-2E”) or polyamide 3 (“PA-3E”).
- Figure 19 is a graphical representation of a quantitative comparison of the ability of polyamide 1 (“PA-IE”), polyamide 2 (“PA-2E”), polyamide 3 (“PA-3E”) or distamycin (Dist”)to inhibit in vitro transcription driven by the HER2/neu promoter when the respective polyamides were presented before exposure to ESX.
- PA-IE polyamide 1
- PA-2E polyamide 2
- PA-3E polyamide 3
- Dist distamycin
- the present invention is directed to methods and compositions for modulating or regulating oncogene expression or overexpression by reducing or inhibiting oncogene transcription, especially of oncogenes involved in cancer, particularly human cancer.
- the reduction in gene transcription results from binding or other interactions between polyamides and the minor groove of dsDNA "within the promoter regions of target oncogenes.
- the polyamides bind or interact with specific target nucleic acid sequences within the promoter regions to inhibit or down-regulate oncogene transcription.
- the sequences are recognized, or proximal to those that are recognized, by one or more transcription factors that bind to or otherwise functionally interact with the promoter region of the targeted oncogene.
- oncogene refers to a gene that causes transformation (i.e., conversion to a tumorigenic, or oncogenic, state) upon expression in a cell.
- Oncogenes can be viral in origin, or they may arise from a mutation (including point mutations (e.g., substitutions, deletions, and insertions), chromosomal rearrangement (e.g., an insertion, translocation, and copy number amplification), or aberrant expression of an endogenous, cellular proto-oncogene.
- point mutations e.g., substitutions, deletions, and insertions
- chromosomal rearrangement e.g., an insertion, translocation, and copy number amplification
- aberrant expression of an endogenous, cellular proto-oncogene At present, about 100 oncogenes have been identified.
- Oncogenes are classified based on activity, and include those that are transmembrane proteins (e.g., cell surface receptors) to transcription factors and other nuclear proteins (e.g., tumor suppressors, for example, p53).
- the generation of an oncogene from a proto- oncogene represents a change of function, more typically, a gain or loss of function, wherein the gene is inappropriately activated, as may be caused by a mutation, constitutive expression, over-expression, or inappropriate regulation of expression.
- Many oncogenic animal viruses are known, and include both DNA and RNA viruses. Examples include polyomaviruses, adenoviruses, hepatitis viruses, and retroviruses.
- retroviral oncogenes and the disease(s) with which they are associated (.see brackets), include src (sarcoma), H-ras (sarcoma, erythroleukemia), K-ras (sarcoma, erythroleukemia), mos (sarcoma), fas (chondrosarcoma), sis (sarcoma), fins fibrosarcoma), fes (fibrosarcoma), jun (fibrosarcoma), fas (sarcoma), myc (carcinoma, sarcoma, myelocytoma), abl (B cell leukemia), rel lymphatic leukemia), erbA (erythroleukemia, fibrosarcoma), erbB (erythroleukemia, fibrosarcoma), and myb (myeloblastic leukemia).
- src sarcoma
- H-ras sarcoma, erythrole
- oncogenes include rel and N-r -s.
- Representative examples of cellular oncogenes include c-myc, c- abl, c-myb, c-erbB, c-K-ras, and mdml, all of which are amplified (in terms of gene copy number) in the various tumors with which they are associated.
- the expression of an oncogene may be elevated in certain tumors, although the gene's coding sequence is unchanged, as occurs with respect to c-myc in some tumors. Expression of c- myc is known to be increased by several mechanisms, for example, by retroviral insertion in the gene's vicinity.
- c-myc expression is believed to result by constitutive transcription initiated from the viral long terminal repeat (LTR) by virtue of its efficient promoter sequence or enhancer.
- LTR long terminal repeat
- Other cellular oncogenes activated by the integration of a retroviral genome include, without limitation, c-erbB, c-myb, c-mos, c-rafi c-wntl, c- int2, and c-H-ras.
- c-myc expression is also known to be increased in some tumors, particularly those of the immune system, as a result of a translocation, as well as by gene amplification.
- the gene products encoded by oncogenes or proto-oncogenes have a variety of cellular functions. Some of these gene products are growth factors (e.g., c-sis, KS/HST, wntl, and int2), growth factor receptors (e.g., the viral, oncogenic counterparts of c-erbB, c-erbB-2 (also known as HER2/neu), erb2,3, c-fins, c-kit, and mas), signal transduction proteins (e.g., c-ras), intracellular tyrosine kinases (e.g., c-src, c-abl, c-fas, v-src, v-yes, v- fgr, v-fas/fes, v-abl, and v-ros), intracellular serine/threonine kinases (e.g., c-raf and c- mos
- a polyamide according to the invention can be applied to inhibit or otherwise down-regulate the expression of any oncogene, whether now known or later discovered.
- the recognition and/or binding sequences of DNA binding proteins that influence regulation of a particular oncogene are identified, polyamides targeted to these sequences are designed and synthesized, after which they can be incorporated into the disclosed compositions, if desired, and be used to inhibit transcription of the desired oncogene, be it in vivo or in vitro.
- the polyamides are preferably cell-permeable and capable of inhibiting gene transcription in vivo, in vitro, or in cell free systems. Appropriate application of such polyamide molecules may be used to inhibit expression or overexpression of viral or endogenous oncogenes as a treatment of various diseases, including cancer.
- the polyamides bind to the minor groove of double stranded DNA in a promoter region that controls the transcription and expression of a target oncogene.
- target oncogenes are endogenous oncogenes involved in cancer formation or progression.
- the transcription of the oncogene is inhibited by modulating the binding of a protein, such a transcription factor, to the same promoter region with which the polyamide binds or interacts.
- the transcription factors are one or more of the following: ESX; ETS; AP-2, and TBP.
- WO 98/35702 which also includes a discussion of polyamide synthesis.
- the present invention includes the use of polyamides that inhibit or modulate the activity of a transcription factor with its particular recognition and/or binding sequence.
- the methods of the invention affect transcription factor activity by use of one or more polyamides that contact or bind the minor groove of dsD ⁇ A. Such contact or binding may inhibit formation of D ⁇ A-transcription factor complexes in the minor groove by direct steric repulsion, allosteric effects, or other mechanisms (e.g., cleavage or chemical modification of the dsD ⁇ A).
- major groove D ⁇ A binding proteins such as
- TBP may be inhibited by a polyamide-induced change in D ⁇ A conformation through association with the neighboring minor groove.
- the expression or overexpression of oncogenes is targeted.
- the oncogenes are those implicated in cancer, and their expression or overexpression is inhibited by polyamides that contact or bind the minor groove in the region of the oncogene promoter.
- the contacted or bound portions of the promoter region are, or are proximal to, transcription factor binding sites.
- the degree of inliibition is preferably large and more preferably enough to inhibit even overexpression of the oncogene, in when the copy number of the gene increases.
- One oncogene target of the invention is the HER-2/neu gene, which may be down-regulated or inhibited by the use of polyamides that bind to target sequences within the HER-2/neu promoter region. Preferably, these sequences are, or are proximal to, transcription factor binding sites within the HER2/neu promoter. These transcription factors include TBP, ESX, and AP-2. Interactions or binding between the polyamide and the target sequence result in inhibition of the HER2/neu gene transcription.
- the present invention includes compositions comprising a pharmaceutically acceptable excipient and a transcription-inhibiting amount of at least one polyamide for the inhibition of gene expression or overexpression. These compositions may also be used for the treatment of various tumors or cancers, including breast cancer.
- the invention further provides methods of administering such compositions to result in inhibition of gene expression or overexpression.
- the methods and compositions are preferably suited for treating a subject having a condition associated with abnormal expression of a cellular oncogene.
- the subject is preferably a human patient particularly one afflicted with cancer, especially breast cancer.
- the nucleotide sequence of the region of the HER2/neu promoter encompassing the ESX binding site is shown in Figure 2A. This region was divided into four overlapping target sites, each consisting of 7 base-pairs. Two polyamides consisting of N-methylimidazole carboxamide residues, N-methylpyrrole carboxamide residues, and none, one or two ⁇ -alanine aliphatic amino acid residues were designed to correspond to the DNA sequence of each of these target sites (Fig. 2B). The sequence of the N- methylimidazole carboxamide residues and N-methylpyrrole carboxamide residues was chosen according to the pairing rules described above.
- Polyamide 1 had the structure ImPy- ⁇ -PyIm-2,4DA-PyPy- ⁇ -ImPy- ⁇ -D ⁇ .
- Polyamide 2 had the structure ImPyPyPyPy- 2,4DA-PyPyPyPyPy- ⁇ -Dp.
- Polyamide 3 had the structure ImPy- ⁇ -PyPy-2,4DA-PyPyc ⁇ - PyPy- ⁇ -Dp.
- Polyamide 4 had the structure ImPyPyPyIm-2,4DA-PyPyPyImPy- ⁇ -Dp.
- Polyamide 5 had the structure ImIm- ⁇ -PyIm-2,4DA-PyPy- ⁇ -PyPy- ⁇ -Dp.
- Polyamide 6 had the structure ImIm- ⁇ -PyIm-2,4DA-PyPyPyPyPy- ⁇ -Dp.
- Polyamide 7 had the structure Im- ⁇ -ImImPy-2,4DA-PyPyPy- ⁇ -Py- ⁇ -Dp.
- Polyamide 8 had the structure Im- ⁇ - ImImPy-2,4DA-PyPyPyPy- ⁇ -Dp.
- the building blocks that are required for the solid-phase synthesis of the polyamides were prepared on large scales (50 to 200 g) according to established procedures. All polyamides were prepared by solid-phase synthesis on a Boc- ⁇ -alanine- PAM resin which is commercially available in appropriate substitution levels (0.615 mmol/g). The synthesis of the polyamide 1 is depicted in Figure 3 as a representative example. All polyamides were characterized by MALDI-MS; the experimentally obtained data were in good agreement with the expected values.
- Figure 4 shows the structural formulas of eight polyamides that have been designed to bind to the ESX binding site, as well as MALDI-MS data that characterize each compound.
- the polyamides of the invention may be formulated into pharmaceutical or therapeutic compositions, formulations, or preparations.
- Pharmaceutically acceptable salts of the polyamide compounds of the invention are formed where appropriate with strong or moderately strong, non-toxic, organic, or inorganic acids or bases by methods known in the art.
- Exemplary of the salts that are included in this invention are maleate, fumarate, lactate, oxalate, methanesulfonate, ethanesulfonate, benzenesulfonate, tartrate, citrate, hydrochloride, hydrobromide, sulfate, phosphate, and nitrate salts.
- polyamide compounds of the invention possess the ability to inhibit oncogene expression or overexpression, properties that are exploited in the treatment of any of a number of diseases or conditions, most notably cancer.
- a composition of this invention may be active per se, or may act as a "pro-drug" that is converted in vivo to an active form.
- the compounds of the invention may be incorporated into convenient dosage forms, such as capsules, impregnated wafers, tablets, or injectable preparations.
- Solid or liquid pharmaceutically acceptable carriers may be employed.
- Pharmaceutical compositions designed for timed release may also be formulated.
- the compounds of the invention are administered systemically, e.g., by injection.
- injection may be by any known route, preferably intravenous, subcutaneous, intramuscular, intracranial, or intraperitoneal.
- injectables can be prepared in conventional forms, either as solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
- Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
- Liquid carriers include syrup, peanut oil, olive oil, saline, water, dextrose, glycerol and the like.
- the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, liquid containing capsule, sterile injectable liquid (e.g., a solution), such as an ampoule, or an aqueous or nonaqueous liquid suspension.
- sterile injectable liquid e.g., a solution
- an ampoule or an aqueous or nonaqueous liquid suspension.
- the pharmaceutical preparations are made following conventional techniques of pharmaceutical chemistry involving such steps as mixing, granulating and compressing, when necessary for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired products for oral or parenteral, including topical, transdermal, intravaginal, intranasal, intrabronchial, intracranial, intraocular, intraaural and rectal administration.
- the pharmaceutical compositions may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and so forth.
- the pharmaceutical composition may be administered topically or transdermally, e.g., as an ointment, cream or gel, orally, rectally, e.g., as a suppository, parenterally, by injection or continuously by infusion, intravaginally, intranasally, intrabronchially, intracranially intra-aurally, or intraocularly.
- the composition may be incorporated into topically applied vehicles such as a salve or ointment.
- the carrier for the active ingredient may be either in sprayable or nonsprayable form.
- Non-sprayable forms can be semi-solid or solid forms comprising a carrier indigenous to topical application and having a dynamic viscosity preferably greater than that of water.
- Suitable formulations include, but are not limited to, solution, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like. If desired, these may be sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, wetting agents, buffers, or salts for influencing osmotic pressure and the like.
- Preferred vehicles for non-sprayable topical preparations include ointment bases, e.g., polyethylene glycol-1000 (PEG-1000), conventional creams such as HEB cream, gels, as well as petroleum jelly and the like.
- sprayable aerosol preparations wherein the compound, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant.
- the aerosol preparations can contain solvents, buffers, surfactants, perfumes, and/or antioxidants in addition to the compounds of the invention.
- a target area e.g., skin surface, mucous membrane, eyes, etc.
- This amount will generally range from about 0.001 mg to about 1 g per application, depending upon the area to be treated, the severity of the symptoms or disease, and the nature of the topical vehicle employed.
- compositions of the invention can also be administered in combination with one or more additional compounds that are used to treat the disease or condition.
- anti-tumor agents such as mitotic inhibitors, e.g., vinblastine; alkylating agents, e.g., cyclophosphamide; folate inhibitors, e.g., methotrexate, pritrexim or trimetrexate, antimetabolites, e.g., 5-fluorouracil and cytosine arabinoside, intercalating antibiotics, e.g., adriamycin and bleomycin, enzymes or enzyme inhibitors, e.g., asparaginase, topoisomerase inhibitors, e.g., etoposide, or biological response modifiers, e.g., interferon.
- mitotic inhibitors e.g., vinblastine
- alkylating agents e.g., cyclophosphamide
- folate inhibitors e.g.
- compositions comprising any known cancer therapeutic in combination with the polyamine analogues and derivatives disclosed herein are within the scope of this invention.
- Typical single dosages of the compounds of this invention are between about 1 ng and about 10 g/kg body weight.
- the dose is preferably between about O.Olmg and about lg/kg body wt. and, most preferably, between about O.lmg and about lOOmg/kg body wt.
- dosages in the range of about 0.01-20% concentration of the compound, preferably 1-5% are suggested.
- a total daily dosage in the range of about 1-500 mg is preferred for oral administration.
- the foregoing ranges are, however, suggestive, as the number of variables in regard to an individual treatment regime is large, and considerable excursions from these recommended values are expected and may be routinely made by those skilled in the art.
- Effective amounts or doses of the compound for treating a disease or condition can be determined using recognized in vitro systems or in vivo animal models for the particular disease or condition.
- many art-recognized models are known and are representative of a broad spectrum of human tumors.
- the compositions may be tested for inhibition of tumor cell growth in culture using standard assays with any of a multitude of tumor cell lines of human or non-human animal origin. Many of these approaches, including animal models, are described in detail in Geran, R.I. et al, "Protocols for Screening Chemical Agents and Natural Products against Animal Tumors and Other Biological Systems (Third Edition)", Cane. Chemother. Reports, Part 3, 3:1- 112.
- the treatment methods of the invention are directed to the administration of polyamide-containing compositions.
- the polyamide-containing preparations of the invention may be administered systemically or locally and may be used alone or as components of mixtures.
- the route of administration may be topical, intravenous, oral, or by use of an implant.
- polyamides may be administered by means including, but not limited to, topical preparations, intravenous injection or infusion, oral intake, or local administration in the form of intradermal injection or an implant. Additional routes of administration are subcutaneous, intramuscular, or intraperitoneal injections of the polyamides in conventional or convenient forms. Liposomal or lipophilic formulations may also be used when desired.
- the polyamides may be in standard topical formulations and compositions including lotions, suspensions or pastes. Oral administration of suitable formulations may also be appropriate in those instances where the polyamides may be readily administered to the target cells or tissues via this route.
- the dose of polyamides may be optimized by the skilled artisan depending on factors such as, but not limited to, the polyamides chosen, the physical delivery system in which it is carried, the individual subject, and the judgment of the skilled practitioner.
- a plasmid containing the HER2/neu promoter from which was prepared a 5'-32p end-labeled 188 base-pair DNA fragment containing the ESX binding site by PCR (polymerase chain reaction).
- Polyamide 4 which does not contain ⁇ -alanine units, showed only weak binding to both the match and the mismatch site, in both cases at [5] of about 5 nM.
- the polyamide 5 showed no significant binding at concentrations of less than 10 nM.
- polyamide 6 did not bind to its designated match site (5'- TGAGGAA-3') at concentrations smaller than 10 nM.
- 6 showed several footprints at other locations of the DNA fragment at concentrations higher than 1 nM.
- polyamide 7 bound to a single base-pair mismatch site (ATGAAGT) with an association constant KQ. of ca. 10 ⁇ M ⁇ l. No binding of polyamide 7 to the match site (5'-AGGAAGT-3') was observed (at [7] ⁇ 10 nM). Polyamide 8 bound weakly to its match site (K a ⁇ 5 nM). However, it did not bind very selectively to the DNA fragment; among other sites it bound to the formal single base-pair mismatch site 5'-ATGAAGT-3' with an association constant KQ, of ca. 1 M" 1.
- the poor binding of polyamides 5 to 8 that were designed to bind to the sites 2 and 3 of the promoter, respectively, may be due to a deviation of the DNA conformation from the B-form in that region.
- the DNA sequence of the AP-2 binding site and adjacent regions is shown in Figure 7A. As in the studies of the ESX binding site, this region was divided into three target sites, each consisting of 6 to 8 base-pairs. For each of these sites, two polyamides were prepared consisting of N-methylimidazole carboxamide residues, N-methylpyrrole carboxamide residues, and none, one or two ⁇ -alanine amino acid residues ( Figure 7B). The sequence of the N-methylimidazole carboxamide residues, N-methylpyrrole carboxamide residues, and ⁇ -alanine amino acid residues was chosen according to the pairing rules described above.
- Polyamide 9 had the structure ImPy- ⁇ -ImPy-2,4DA- PyPylmlmPy- ⁇ -Dp.
- Polyamide 10 had the structure ImPy- ⁇ -ImPy-2,4DA-Py- ⁇ - ImlmPy- ⁇ -Dp.
- Polyamide 11 had the structure ImPyPy- ⁇ -ImPy-2,4DA-ImPy- ⁇ - ImlmPy- ⁇ -Dp.
- Polyamide 12 had the structure ImPy- ⁇ -ImImPy-2,4DA-ImPyPy- ⁇ - ImPy- ⁇ -Dp.
- Polyamide 13 had the structure ImImPyPy-2,4DA-PyImPyPy- ⁇ -Dp.
- the polyamides were prepared by solid-phase synthesis. Their purity was confirmed by analytical HPLC and their structures confirmed by MALDI-MS. The structures are shown in Figure 8.
- a 5-32p end-labeled 189 base-pair DNA fragment containing the AP-2 binding site was obtained by PCR from the HER2/neu plasmid described above.
- Quantitative DNase I footprint titrations (lOmM Tris-HCl, 10 mM KCl, 10 mM MgC_2, and 5 mM CaCl2, pH 7.0 and 22-24 degrees C) were performed to determine the equilibrium association constants (KQ) of each polyamide (9-13) to its respective match sequence.
- KQ equilibrium association constants
- polyamide 10 which contains
- Polyamides 1, 2 and 3 were studied in greater detail and compared to the known compound distamycin.
- SKBR-3 cells were purchased from ATCC (Rockville, MD). Cells were grown in McCoy's 5a medium (GIBCO, Grand Island, NY) with 10% fetal bovine serum and cultured at 37 °C with 5% CO 2 . Nuclear Extract preparation
- SKBR-3 cells that were grown to subconfluence were rinsed twice with Phosphate-buffered saline, scraped, and collected by cenfrifugation at 1,200 rpm for 5 rnin., 4 °C (Sorvall RT6000, Newtown, CT). The following steps were performed at 4 °C.
- Cell pellets were suspended in five times the packed cell volume in buffer A (containing 10 mM Hepes-KOH [ph 7.9], 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA.
- the pellet was resuspended in buffer B and 20 mM Hepes-KOH (ph 7.9), 20% glycerol, 0.2 mM EDTA, 2.0 mM EGTA, 0.75 mM spermidine, 0.15 mM spermine, 2 mM dithiothreitol, and 1 mM phenylmethylsufonyl fluoride followed by drop addition of an equal volume of buffer B that included 0.75 M NaCl. After rocking for 20 min.
- ESX protein Bacterial-expressed ESX protein was prepared as described [Chang et al, 1997]. Briefly, full-length ESX cDNA was cloned into a pRSET his-tag expression plasmid (Nhel-Hindlll; Invitrogen). Expression of ESX protein was processed by transformation of bacterial cells (BL21[DE3] pLysS competent bacterial cells: Stratagene, La Jolla, CA), and induced by addition of IPTG. His-tagged ESX protein was purified using nickel-chelate affinity chromatography as recommended by the manufacturer (Quiagen, Inc., Chatsworth, CA). AP-2 protein was purchased from Promega Co. (Madison, WI). Antibodies against AP-2 were purchased from Santa Cruz Co. (La Jolla, CA), and antibodies against ESX were prepared as described previously. Oligonucleotides
- oligo oligonucleotide containing the ESX protein binding site (derived from HER2 gene promoter; TA5-oligo) and its complementary strand were synthesized from the Biopolymers facility (RPCI, Buffalo, NY) (sequence is shown in Fig. 1A). Oligos were gel-purified, annealed, and end-labeled with ⁇ - 32 P-[ATP] using T4- polynucleotide kinase (New England BioLabs, Beverly, MA) as described previously (10). 32 P-labeled 5' end-overhanging doubled-stranded oligo was used as the probe in gel mobility shift assays.
- the protein-DNA complex was quantitated using a computing laser densitometer (Molecular Dynamics, Sunnyvale, CA). The amount of protein which could complex with >90% of 32 P-labeled oligo was used for most experiments. Identification of protein-DNA complexes was confirmed by adding specific antibodies against proteins to the reaction.
- polyamides The ability of polyamides to interfere with the formation of the ESX-DNA complex was examined by a gel mobility shift assay. Assays were performed to determine the ability of polyamides to inhibit ESX-DNA complex under equilibrium conditions. Experiments were set up to incubate polyamides with 32 P-labeled oligo at room temperature for 30 min. prior to the addition of ESX protein, or to complex ESX protein with the probe before adding polyamides. The inhibition of ESX-DNA complex formation by polyamides was measured by comparing drug-treated with non drug-treated samples. Investigation of the ability of polyamides to inhibit the AP-2-DNA complex was carried out in a similar manner. IC 50 (concentration of drug required for 50% inhibition of protein-DNA complex formation) was used to express the activity of polyamides. Drug concentrations for IC 50 were also expressed as r values (the molar ratio of drug to DNA base pairs).
- CsCl-purified plasmid DNA composed of an insert DNA fragment from the HER2 promoter in the vector pCDNA3-Lue (Invitrogen, Carlsbad, CA), was linearized with restriction enzyme Sphl (New England BioLabs, Beverly, MA) and used as a DNA template.
- the reaction was stopped by adding 325 ⁇ L of 10 mM Tris-base (pH 8.0), 7 M urea, 350 mM NaCl, 1% SDS, and 100 ⁇ g tRNA, followed by phenol-chloroform-isoamyl alcohol extraction and ethanol precipitation. Samples were resuspended in formamide-loading dye and heated at 90 ⁇ 95 °C for > 1 min. before loading onto a 4%, 7 M urea-polyacrylamide gel. The 3 P signal from a dried gel was visualized using a Phosphorimager screen and quantitated with a computing laser densitometer (Molecular Dynamics, Sunnyvale, CA). The reaction was optimized by titration of nuclear extracts against 1 ⁇ g of DNA template in which a saturated condition was used for drug studies.
- polyamides The ability of polyamides to inhibit in vitro transcription was analyzed in two ways, (i) DNA template was incubated with polyamides at the indicated concentrations in a total volume of 10 ⁇ L, for 30 min. prior to the addition of nuclear extracts and nucleotides. (ii) Pre-incubation of nuclear extracts and DNA template for 15 min. was followed by addition of polyamides for another 30 min. in a total volume of 10 ⁇ L and then nucleotides were added. All experiments were performed at 30 °C and the transcription reaction was allowed to proceed for 60 min. Percentage of inhibition of transcription was measured by comparing samples treated with polyamides to an untreated control. IC 50 and r values were used to express the activity of polyamides. T3 transcript (250 bases; Promega Co., Madison, WI) was used as an internal control.
- Figure 13 shows the results of gel experiments results that demonstrate the binding of an oligonucleotide containing the ESX binding site of the HER2/neu promoter and the ESX protein in the presence of various concentrations of polyamide 2 ("PA-2E") or distamycin.
- PA-2E polyamide 2
- Polyamide 2 ImPyPyPyPy-R2,4D-PyPyPyPyPy- ⁇ -Dp, blocked the binding of ESX protein to DNA in the concentration range of about 1 nM to about 100 nM.
- distamycin blocked the binding of ESX protein to DNA in the concentration range of about 1 ⁇ M to about 10 ⁇ M.
- PA-2E and distamycin target a similar portion (site 2) of the ESX DNA binding domain.
- a gel mobility shift assay was utilized to examine the activities of drugs on the
- FIG 19 is a graphical representation of a quantitative comparison of the ability of polyamide 1 ("PA- IE”), polyamide 2 (“PA-2E"), polyamide 3 (“PA-3E") or distamycin ("Dist”) to inhibit in vitro transcription driven by the HER2/neu promoter when the respective polyamides were presented before exposure to ESX.
- the concentrations producing half-maximum inhibition were about 3 ⁇ M, about 1 ⁇ M, about 2.3 ⁇ M and about 7.3 ⁇ M, respectively.
Abstract
L'invention concerne des polyamides capables d'inhiber la transcription d'oncogènes. De préférence, les polyamides comprennent au moins trois paires complémentaires de résidus de carboxamides aromatiques se liant au sillon mineur d'un ADN à double brin. En ce qui concerne chaque polyamide, l'appariement complémentaire de quelques-uns ou de la totalité des résidus de carboxamides aromatiques du polyamide détermine la séquence nucléotidique cible d'une cible d'ADN à double brin identifiée dans la région d'activation d'un oncogène.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002342278A CA2342278A1 (fr) | 1998-09-11 | 1999-09-10 | Inhibition de transcription d'oncogenes par des polyamides synthetiques |
JP2000570300A JP2003505521A (ja) | 1998-09-11 | 1999-09-10 | 合成ポリアミドによる癌遺伝子転写の阻害 |
EP99946779A EP1112267A2 (fr) | 1998-09-11 | 1999-09-10 | Inhibition de transcription d'oncogenes par des polyamides synthetiques |
AU59108/99A AU5910899A (en) | 1998-09-11 | 1999-09-10 | Inhibition of oncogene transcription by synthetic polyamides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9985498P | 1998-09-11 | 1998-09-11 | |
US60/099,854 | 1998-09-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000015773A2 WO2000015773A2 (fr) | 2000-03-23 |
WO2000015773A3 WO2000015773A3 (fr) | 2000-08-17 |
WO2000015773A9 true WO2000015773A9 (fr) | 2002-04-25 |
Family
ID=22276927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/020489 WO2000015773A2 (fr) | 1998-09-11 | 1999-09-10 | Inhibition de transcription d'oncogenes par des polyamides synthetiques |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1112267A2 (fr) |
JP (1) | JP2003505521A (fr) |
AU (1) | AU5910899A (fr) |
CA (1) | CA2342278A1 (fr) |
WO (1) | WO2000015773A2 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122626B2 (en) | 2001-04-26 | 2006-10-17 | Genesoft Pharmceuticals, Inc. | Halogen-substitued thienyl compounds |
WO2002101007A2 (fr) | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc | Composes benzamides anti-pathogenes |
US6777425B2 (en) | 2001-06-13 | 2004-08-17 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
EP1470119A4 (fr) | 2001-06-13 | 2005-10-19 | Genesoft Pharmaceuticals Inc | Composes benzothiophene presentant une activite anti-infectieuse |
AU2002312371A1 (en) | 2001-06-13 | 2002-12-23 | Roland W. Burli | Aryl-benzimidazole compounds having antiinfective activity |
DE60326735D1 (de) | 2002-08-02 | 2009-04-30 | Genesoft Pharmaceuticals Inc | Biaryl-verbindungen mit antiinfektiver wirkung |
US7265129B2 (en) | 2002-10-25 | 2007-09-04 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
JP2006509027A (ja) | 2002-12-10 | 2006-03-16 | オーシェント ファーマシューティカルズ コーポレーション | (ピロールカルボキサミド)−(ベンズアミド)−(イミダゾールカルボキサミド)モチーフを有する抗菌化合物 |
WO2007034784A1 (fr) * | 2005-09-20 | 2007-03-29 | Nihon University | Inhibiteur de l'expression du gène du ctgf |
WO2007103584A2 (fr) * | 2006-03-09 | 2007-09-13 | Nanovir, Llc | Polyamides pour le traitement du virus du papillome humain |
US8993609B2 (en) | 2006-05-04 | 2015-03-31 | Nanovir, Llc | Compounds for treating papilloma virus infection |
EP2013200B1 (fr) | 2006-05-04 | 2012-04-25 | Nanovir, LLC | Polyamides destines au traitement du papillomavirus humain |
US9982020B2 (en) | 2011-10-10 | 2018-05-29 | Nanovir Llc | Antiviral compounds and methods for treating infections caused by double-stranded DNA viruses |
BR112014008464A2 (pt) | 2011-10-10 | 2017-04-11 | Nanovir Llc | composto; composição farmacêutica; método para ligar dna de fita dupla com especificidade para sequência; método para reduzir ou inibir a proliferação de células de papiloma ou neoplásticas; método para tratar células infectadas por vírus; e método para tratar hpv em um indivíduo |
US10723716B2 (en) | 2016-12-21 | 2020-07-28 | New York University | Alpha-helix mimetics as modulators of Abeta self-assembly |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU734715B2 (en) * | 1996-02-26 | 2001-06-21 | California Institute Of Technology | Improved polyamides for binding in the minor groove of double stranded DNA |
EP0973740A1 (fr) * | 1996-02-26 | 2000-01-26 | California Institute Of Technology | Conception, synthese et utilisation de ligands a base de polyamides specifiques pour liaison a l'adn |
CA2280806A1 (fr) * | 1996-08-01 | 1998-08-20 | California Institute Of Technology | Inhibition de la transcription de genes par des ligands de polyamide se fixant a l'adn |
EP0986539A1 (fr) * | 1997-04-06 | 2000-03-22 | California Institute Of Technology | Derives de polyamides pyrrole-imidazole liant l'adn |
-
1999
- 1999-09-10 WO PCT/US1999/020489 patent/WO2000015773A2/fr not_active Application Discontinuation
- 1999-09-10 JP JP2000570300A patent/JP2003505521A/ja active Pending
- 1999-09-10 AU AU59108/99A patent/AU5910899A/en not_active Abandoned
- 1999-09-10 CA CA002342278A patent/CA2342278A1/fr not_active Abandoned
- 1999-09-10 EP EP99946779A patent/EP1112267A2/fr not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000015773A9 (fr) | Inhibition de transcription d'oncogenes par des polyamides synthetiques | |
EP1112267A2 (fr) | Inhibition de transcription d'oncogenes par des polyamides synthetiques | |
US20210322439A1 (en) | Compositions and methods for treating patients with rtk mutant cells | |
Sheng et al. | Structure‐based DNA‐targeting strategies with small molecule ligands for drug discovery | |
JP2023011614A (ja) | 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法 | |
Chiang et al. | Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA | |
AU749953B2 (en) | Inhibition of gene transcription by polyamide DNA-binding ligands | |
KR20030043785A (ko) | 핵산 결합 부위를 포함하는 하전된 화합물 및 이의 용도 | |
JP2010539104A (ja) | ヒストンデアセチラーゼhdac1、hdac2および/またはhdac3の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療 | |
AU768405B2 (en) | Regulation of HER2/neu oncongene expression by synthetic polyamides | |
KR20030040554A (ko) | 티에노피리미딘-기초한 src 계통군의 저해물질 | |
ZA200502384B (en) | Non-nucleoside reverse transcriptase inhibitors | |
JP2002504095A (ja) | Hiv逆転写酵素阻害剤として有用な4,4−二置換−3,4−ジヒドロ−2(1h)−キナゾリノン | |
WO1998043969A1 (fr) | Indazoles d'urees cycliques utiles comme inhibiteurs de vih protease | |
Kabir et al. | Probing the interaction of spermine and 1-naphthyl acetyl spermine with DNA polynucleotides: a comparative biophysical and thermodynamic investigation | |
CA2281843A1 (fr) | Regulation stereochimique de l'affinite de fixation a l'adn, specificite de sequence, et preferences d'orientation de polyamides en epingle a cheveux chiraux dans le sillon mineur | |
Pandya et al. | G-quadruplex-mediated specific recognition, stabilization and transcriptional repression of bcl-2 by small molecule | |
US7351531B2 (en) | Molecules capable of binding to telomere and the like and method with the use of the same | |
JP6965432B2 (ja) | キノリンおよびナフチリジンの誘導体および組成物 | |
JP2002539077A (ja) | 二本鎖核酸とのヌクレオチド塩基対−特異的相互作用を受ける環状化合物に関する組成物および方法 | |
TW517053B (en) | Sulfonamid-substituted chromans having K+ channel blocking action, process for their preparation, their use as medicament, and pharmaceutical preparation containing them | |
WO2019230669A1 (fr) | Composition pharmaceutique ciblant une séquence de liaison au runx, et inhibiteur du runx | |
EP2336108A1 (fr) | Composés hybrides tripyrrol-octaarginine et utilisation de ceux-ci en tant que médicament pour traiter le cancer et les maladies microbiennes | |
US20130203789A1 (en) | Novel Inhibitors of LYN Kinase and Methods Using Same | |
KR20060002827A (ko) | 질병에 관계되는 유전자의 특이적인 동시 억제를 위한화합물 및 이의 용도 및 관련 약물 |